Thermo Fisher Scientific Inc. $TMO Stock: HF Advisory Group LLC Trims Position

HF Advisory Group LLC lowered its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 54.2% in the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,129 shares of the medical research company’s stock after selling 1,337 shares during the period. HF Advisory Group LLC’s holdings in Thermo Fisher Scientific were worth $762,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Bank OZK purchased a new position in Thermo Fisher Scientific during the second quarter valued at $1,096,000. Ausdal Financial Partners Inc. bought a new position in shares of Thermo Fisher Scientific in the second quarter worth approximately $456,000. BlackRock Inc. bought a new stake in shares of Thermo Fisher Scientific during the second quarter valued at approximately $15,501,867,000. German American Bancorp Inc. bought a new position in Thermo Fisher Scientific in the 2nd quarter valued at approximately $4,920,000. Finally, Parallax Volatility Advisers L.P. bought a new stake in shares of Thermo Fisher Scientific in the 2nd quarter worth $814,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Thermo Fisher Scientific

In other news, CAO Joseph Holmes sold 420 shares of Thermo Fisher Scientific stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $584.81, for a total transaction of $245,620.20. Following the transaction, the chief accounting officer directly owned 2,966 shares of the company’s stock, valued at $1,734,546.46. The trade was a 12.40% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $565.00, for a total transaction of $226,000.00. Following the completion of the sale, the chief operating officer directly owned 24,651 shares of the company’s stock, valued at $13,927,815. This represents a 1.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 73,768 shares of company stock valued at $44,122,820. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Up 1.0%

Shares of TMO stock opened at $658.23 on Friday. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a 12 month low of $435.27 and a 12 month high of $694.33. The stock has a market cap of $243.38 billion, a P/E ratio of 35.41, a P/E/G ratio of 2.73 and a beta of 0.87. The company has a 50 day simple moving average of $627.39 and a two-hundred day simple moving average of $541.36.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. During the same quarter in the previous year, the firm posted $4.28 EPS. The company’s revenue for the quarter was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, research analysts expect that Thermo Fisher Scientific Inc. will post 25.13 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Stifel Nicolaus set a $650.00 price objective on Thermo Fisher Scientific in a research report on Wednesday, August 5th. Wells Fargo & Company cut shares of Thermo Fisher Scientific from an “overweight” rating to an “underweight” rating in a research note on Wednesday, September 9th. Weiss Ratings raised shares of Thermo Fisher Scientific from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday. Citigroup cut shares of Thermo Fisher Scientific from a “buy” rating to an “underperform” rating in a report on Wednesday, September 9th. Finally, Scotiabank started coverage on shares of Thermo Fisher Scientific in a report on Wednesday, September 9th. They issued an “outperform” rating on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and a consensus target price of $634.86.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company’s portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.